Scarica l'app Stockscreener
1.94
2.51%
-0.05
Dopo l'orario di chiusura:
1.92
-0.02
-1.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRBU Giù?
Forum
Previsione
Caribou Biosciences Inc Borsa (CRBU) Ultime notizie
CRBU SEC FilingsCaribou Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Caribou Biosciences, Inc. (CRBU) stock price, news, quote and history - sg.finance.yahoo.com
Alpha Cognition Inc. (ACOG) Jumps 8.6%: Does the Stock Have More Room to Grow? - Bitget
CRBU Stock Price, Quote & Chart | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill
Caribou Biosciences Granted FDA RMAT Designation for CB-011 Allogeneic Anti-BCMA CAR-T Cell Therapy - Minichart
Caribou Biosciences, Inc. Announces the FDA Granted Regenerative Medicine Advanced Therapy Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy - MarketScreener
Caribou Biosciences Gains RMAT Status for CB-011 Therapy - TipRanks
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy - Investing News Network
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy - Bitget
Caribou rises on FDA RMAT designation (CRBU:NASDAQ) - Seeking Alpha
Caribou Biosciences Announces The FDA Granted Regenerative Medicine Advanced Therapy (Rmat) Designation To Cb-011 - TradingView
Caribou Biosciences receives FDA RMAT designation for CB-011 in multiple myeloma - tradersunion.com
FDA grants RMAT designation to Caribou (CRBU) CAR-T CB-011 in multiple myeloma - Stock Titan
FDA gives advanced therapy status to Caribou's myeloma CAR-T - Stock Titan
Fed Watch: Can Caribou Biosciences Inc expand its profit marginsMarket Activity Recap & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Is Caribou Biosciences Inc a cyclical or defensive stockWeekly Trade Recap & High Conviction Buy Zone Picks - baoquankhu1.vn
Caribou Biosciences (NASDAQ:CRBU) Stock Rating Upgraded by Truist Financial - marketbeat.com
Hedge Fund Moves: Is Caribou Biosciences Inc stock good for income investors2026 Retail Activity & Daily Market Momentum Tracking - baoquankhu1.vn
How does Caribou Biosciences Inc compare to its peersPortfolio Gains Report & Fast Gaining Stock Reports - baoquankhu1.vn
Caribou Biosciences stock faces pressure amid biotech volatility and pipeline updates - AD HOC NEWS
Caribou Biosciences Shares Double After Strong Multiple Myeloma Trial Results - msn.com
Market Catalysts: Is Caribou Biosciences Inc benefiting from interest rate changesWeekly Risk Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
CRBU Earnings History & Surprises | EPS & Revenue Results | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill
Trading Action: How does Caribou Biosciences Inc compare to its peersInsider Buying & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value - Seeking Alpha
Caribou Biosciences Teases vispa-cel Phase 3 LBCL Plan, Eyes Financing at Leerink Conference - MarketBeat
CRBU Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Analysts Are Bullish on Top Healthcare Stocks: Caribou Biosciences (CRBU), Oncology Institute (TOI) - The Globe and Mail
Drug Pricing Reforms Threaten Caribou Biosciences’ Future Margins and Market Access - The Globe and Mail
Caribou Biosciences: Advancing Allogeneic Cell Therapy Pipeline and Pivotal Trial Plans Support High-Risk Buy Rating - TipRanks
Truist reiterates Buy on Caribou Biosciences stock, $7 target - Investing.com Australia
Truist reiterates Buy on Caribou Biosciences stock, $7 target By Investing.com - Investing.com UK
Caribou Biosciences, Inc. (CRBU) reports Q4 loss, tops revenue estimates - MSN
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Investing News Network
Caribou Biosciences earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Caribou Biosciences (NASDAQ:CRBU) Posts Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
Caribou Biosciences announces Q4 and FY2025 financial results - Traders Union
Caribou Biosciences Q4 licensing revenue rises, net loss narrows - TradingView
Insights into Caribou Biosciences Q4 Earnings - Benzinga
Caribou Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
CRBU: Strong clinical progress and improved financials position the pipeline for pivotal trials - TradingView
Caribou Biosciences (Nasdaq: CRBU) details 2025 loss and CAR-T trial plans - Stock Titan
BRIEF-Caribou Biosciences Q4 Licensing And Collaboration Revenue USD 3.941 Million - TradingView
Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments - Stocktwits
Cancer CAR-T developer Caribou has $142.8M to fund trials into 2H 2027 - Stock Titan
CRBU Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Caribou Biosciences (CRBU) to Release Earnings on Monday - MarketBeat
Insider Sell: Timothy Kelly Sells Shares of Caribou Biosciences Inc (CRBU) - GuruFocus
Caribou Biosciences Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Caribou Biosciences (CRBU) CTO sells 6,228 shares in open-market trade - Stock Titan
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):